Proteomics International
Proteomics International is a Perth-based medical technology company developing proprietary proteomics-based blood diagnostic tests for early disease prediction in diabetes, cancer, and endometriosis, commercialized via licensing partners, laboratory services, and direct-to-consumer channels.
- Company typePublic
- Founded2001
- HeadquartersPerth, Australia
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Proteomics International does
Proteomics International is a Perth-based medical technology company founded in 2001 and listed on the ASX (ticker: PIQ) that develops proteomics-based diagnostic tests for the early detection and prediction of disease. The company's core technology uses mass spectrometry to identify proprietary protein biomarker panels in blood, which are combined into diagnostic algorithms delivered through its PromarkerHub software platform. Lead commercial product PromarkerD is a predictive blood test for diabetic kidney disease, with pipeline products including PromarkerEso (esophageal cancer), PromarkerEndo (endometriosis), and OxiDx (oxidative stress). PromarkerHub uses traditional statistical methods (logistic regression with fixed coefficients) rather than AI/ML models, prioritizing regulatory interpretability.
The company operates a hybrid business model combining licensing and distribution partnerships (notably an exclusive US license with Sonic Healthcare, plus regional partners Atturos for Europe, Patia for Mexico, and PrismHealthDx for Asia-Pacific), direct laboratory and analytical services (including pharmacokinetics and biomarker discovery for clients such as Avance Clinical and Sironax), and a direct-to-consumer channel via MyTest.health. The company holds patents in 13+ jurisdictions and maintains regulatory certifications including CAP, CLIA, ISO 13485, ISO 17025, CE Mark, and TGA, with CAP accreditation for its US Reference Laboratory secured in December 2025.
The company's customer base is concentrated, with revenue showing significant quarter-to-quarter volatility driven by individual large contracts (Q3 2025 revenue of A$1.9M was approximately seven times Q3 2024's A$253k, materially influenced by a single UWA analytical services contract). With 11-50 employees, recent product launches, and an active international expansion program, Proteomics International sits at an early commercial stage transitioning from analytical services revenue toward scaled diagnostic product sales, particularly through the US Sonic Healthcare channel.
Proteomics International firmographics
Firmographics- Name
- Proteomics International
- Legal name
- Proteomics International Laboratories Ltd
- Website
- https://proteomics.com.au
- Company type
- Public
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Proteomics International is a Perth-based medical technology company developing proprietary proteomics-based blood diagnostic tests for early disease prediction in diabetes, cancer, and endometriosis, commercialized via licensing partners, laboratory services, and direct-to-consumer channels.
- Ownership category
- akta.pro rank
Proteomics International industry classification
Industry- Product category
- Proteomics Diagnostics
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Services-Medical Laboratories (8071), Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Proteomics & Mass Spectrometry Services (HLAGANAB)
- akta.pro secondary industries
- Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), DMPK / ADME & Bioanalysis (HLAGAFAC)
Keywords
Where Proteomics International is headquartered
LocationHeadquarters
- HQ city
- Perth
- HQ country
- Australia
- HQ region
- Oceania
Offices4 records
Markets served
Proteomics International business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Diagnostic Test Sales: Revenue from sales of Promarker branded diagnostic tests through direct laboratory services and licensing agreements with regional partners.
- Analytical Services: Cutting-edge accredited analytical services on commercial scale including pharmacokinetic testing, biomarker discovery and validation, biosimilars/biologics drug characterisation, and specialist protein testing. ISO 17025 accredited.
- Licensing Royalties: Ongoing royalties from licensing agreements with partners such as Sonic Healthcare USA, Atturos (Europe), Patia (Mexico), and other international distributors.
- R&D Tax Incentives: Australian Government R&D Tax Incentive rebates for eligible research and development expenditure. Received $2.2M rebate in November 2025.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | PromarkerD diagnostic test - US market reimbursement price established |
| Unit Pricing | Pay-as-you-go | Healthcare provider ordered testing via referral form |
Go-to-market motion2 records
Distribution channels6 records
Marketing channels6 records
Proteomics International product offering
Product offeringCore offering
Proteomics International develops and commercializes proprietary protein biomarker-based blood tests (the Promarker® platform, including PromarkerD for diabetic kidney disease, PromarkerEso for esophageal adenocarcinoma, PromarkerEndo for endometriosis, and OxiDx for oxidative stress) alongside ISO 17025-accredited analytical services (pharmacokinetic testing, biomarker discovery and validation, and biosimilars/biologics drug characterization). Its core revenue comes from licensing these diagnostic tests to healthcare providers and regional partners (e.g., Sonic Healthcare USA, Atturos, Patia), operating its own CLIA/CAP-accredited reference laboratories in the US and Australia, and selling professional analytical services to pharmaceutical and biotech clients.
Product overview
Proteomics International operates a platform-plus-products architecture centered on its Promarker® proteomics platform. The core offering consists of four diagnostic products: PromarkerD (diabetic kidney disease prediction), PromarkerEso (esophageal cancer detection), PromarkerEndo (endometriosis diagnosis), and OxiDx (oxidative stress). These products are supported by the PromarkerHub cloud-based analysis platform which runs proprietary algorithms to calculate risk scores. Additionally, the company offers analytical services (pharmacokinetics, biomarker discovery, biosimilars characterization) as a revenue stream that complements product development. All testing is powered by the company's proteomics expertise - the industrial-scale study of protein structure and function.
Differentiator
Problem solved
Functional benefit
Brands
- PromarkerD: World-first predictive blood test for diabetic kidney disease (DKD), predicting the onset up to four years before symptoms appear.
- PromarkerEso
- PromarkerEndo
- OxiDx
- Promarker Hub
- MyTest
Products and services
- PromarkerD A world-first blood test that predicts the risk of diabetic kidney disease (DKD) up to four years before symptoms appear by analysing protein biomarkers combined with clinical factors in a proprietary algorithm to calculate a risk score. Licensed in the US exclusively to Sonic Healthcare USA, distributed regionally via Atturos (Europe), Patia (Mexico) and PrismHealthDx, and available direct-to-consumer through MyTest.health in Australia and the company's US CLIA/CAP-accredited laboratory. Patented in the US, Europe, Japan, China, India, Hong Kong, Russia, Indonesia, Brazil, Canada, Singapore and Australia.
- PromarkerEso A blood test that detects specific protein changes (proteomic biomarkers) with high accuracy to rule out esophageal adenocarcinoma (EAC) in patients with chronic reflux, with 99.9% negative predictive value and 91.4% sensitivity. Intended for gastroenterologists and GPs managing GORD patients as a non-invasive rule-out ahead of endoscopy, with US launch planned for 2026 following US patent grant and CAP accreditation.
- PromarkerEndo A first-in-class blood test validated to diagnose endometriosis, including in early stages of the disease, using protein biomarkers to enable non-invasive diagnosis without surgical laparoscopy. In development under an expanded University of Melbourne and Royal Women's Hospital research collaboration, with commercialisation grant funding in place; not yet commercially launched.
- OxiDx A diagnostic product for oxidative stress measurement and a platform technology within the company's pipeline of novel diagnostic tests, leveraging the same proprietary proteomics expertise used in the Promarker® portfolio.
- PromarkerHub A cloud-based results analysis platform that runs proprietary algorithms for each Promarker test, combining biomarker and clinical factors in pre-defined logistic regression equations with fixed coefficients to determine risk scores. Marketed as a CE Marked software IVD (PromarkerD Hub) supporting clinical decision-making, not an AI system.
- Analytical Services Cutting-edge, ISO 17025-accredited analytical services delivered on a commercial scale to pharmaceutical and biotech clients, including pharmacokinetic testing, biomarker discovery and validation, biosimilars/biologics drug characterisation, and specialist protein testing. Underpins enterprise contracts such as the A$243,000 Avance Clinical pharmacokinetic engagement and the A$409,000 Sironax Ltd Phase I clinical trial contract.
Quantifiable outcome
- PromarkerD correctly predicted 86% of patients who developed CKD within four years in 447-patient study
- +7 more outcomes
Companies that use Proteomics International
Customer profileNamed customers10 records
Segments6 records
Ideal customer profiles5 records
Proteomics International technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Proteomics International partnerships and signals
Strategic signalScale indicators12 records
Recent moves7 records
Expansion highlights5 records
Proteomics International competitors and assessment
Company assessmentBroad incumbents
- Exact Sciences: Commercial-stage diagnostics leader in non-invasive cancer screening (Cologuard, Oncotype); relevant as a peer in blood-based and biomarker-based diagnostic test commercialization, payor engagement, and US go-to-market scale-up.
- Myriad Genetics: Established molecular diagnostics company with multi-product portfolio (hereditary cancer, pharmacogenomics, prenatal); relevant as a small-to-mid-cap public peer pursuing predictive blood-based diagnostics with US payor coverage.
- Olink Holding: Provides high-throughput proteomics platforms (Olink Explore, Target) widely used in biomarker discovery and translational research; a relevant technology peer given Proteomics International's LC-MS biomarker discovery infrastructure.
- Bio-Techne: Diversified life-science tools and diagnostics company with proteomics reagents, biomarker assay kits, and diagnostic offerings (e.g., ExoDx); comparable as a protein-based tools + diagnostics peer with global reach.
- SomaLogic (now part of Standard BioTools): Operates a large-scale proteomics platform (SomaScan) used for biomarker discovery and clinical research, with growing IVD/health offerings; comparable in core proteomics technology and biomarker services to Proteomics International's discovery platform.
- Natera: Public diagnostics company commercializing blood-based tests across oncology and women's health (Signatera, Empower, Vistara); directly comparable to the endometriosis (PromarkerEndo) and oncology (PromarkerEso) development ambitions.
- Eurofins Scientific: Global laboratory services group with extensive bioanalytical, PK, and clinical diagnostics capabilities; relevant peer to Proteomics International's ISO 17025 analytical services business (PK testing, biosimilar characterization).
Direct peers
- Biodesix: Proteomics/multi-omic blood-based diagnostic company with a portfolio of lung and broader oncology tests using mass spectrometry and proprietary algorithms; similar proteomics discovery-to-IVD commercialization model and small-cap public profile.
- Renalytix AI: Commercial-stage diagnostics company with KidneyIntelX, a blood-based test that predicts kidney disease progression in type 2 diabetes — directly comparable to PromarkerD in product, target patient population, and commercial pathway (US reimbursement, payor engagement).
Others
- Sonic Healthcare: Global diagnostic pathology/laboratory services provider and exclusive US licensee of PromarkerD; both partner and channel-relevant comparable given the integrated laboratory + commercial-distribution role Sonic plays for Proteomics International in the US market.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Proteomics International social profiles
Digital presenceProteomics International compliance and trust
Trust signalCompliance9 records
Proteomics International financial estimates
Financial estimateRevenue estimate
Valuation estimate
Proteomics International leadership team
Management profileNumber of profiles
Profiles4 records
Proteomics International funding detail
Funding detailFunding overview
Funding rounds5 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Proteomics International M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Proteomics International
What does Proteomics International do?
Proteomics International develops and commercializes proprietary protein biomarker-based blood tests (the Promarker® platform, including PromarkerD for diabetic kidney disease, PromarkerEso for esophageal adenocarcinoma, PromarkerEndo for endometriosis, and OxiDx for oxidative stress) alongside ISO 17025-accredited analytical services (pharmacokinetic testing, biomarker discovery and validation, and biosimilars/biologics drug characterization). Its core revenue comes from licensing these diagnostic tests to healthcare providers and regional partners (e.g., Sonic Healthcare USA, Atturos, Patia), operating its own CLIA/CAP-accredited reference laboratories in the US and Australia, and selling professional analytical services to pharmaceutical and biotech clients.
Is Proteomics International a public or private company?
Proteomics International is a public company. It is classified as public and is currently operating.
When was Proteomics International founded?
Proteomics International was founded in 2001. It employs 11 to 50 people.
Where is Proteomics International based?
Proteomics International is headquartered in Perth, Australia, in the Oceania region.
How does Proteomics International make money?
Four revenue lines are on record. Diagnostic Test Sales are the primary driver. The others are analytical Services, licensing Royalties and R&D Tax Incentives.
Who are Proteomics International's main competitors?
Broad incumbents on record are Exact Sciences, Myriad Genetics, Olink Holding, Bio-Techne, SomaLogic (now part of Standard BioTools), Natera and Eurofins Scientific. Direct peers are Biodesix and Renalytix AI. Sonic Healthcare is listed as an others.
Does Proteomics International have an API?
No public API is recorded for Proteomics International.
What industry is Proteomics International in?
Proteomics International's product category is Proteomics Diagnostics. Its primary akta.pro industry code is HLAGANAB, Proteomics & Mass Spectrometry Services, with a secondary code of HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity). Its NAICS code is 621511 and its SIC code is 8071.